Stockreport

Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

ACHISON INC A  (ACHN) 
Last achison inc a earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.achillion.com/investor-relations
PDF ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investig [Read more]